A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
Clinical trial NCT06238843 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06238843
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-30
- Primary completion
- 2026-12-30
- Enrollment
- 464
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.